Citadel Advisors’s Rosetta Genomics Ltd. ROSG Stock Holding History

Citadel Advisors’s Portfolio ROSG Stock Details ROSG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,545	Closed	-$18K	–	8480
2016 Q4	$18K	Buy	+3,545	New	+$27.1K	﹤0.01%	7107
2016 Q2	–	Sell	-2,161	Closed	-$28K	–	7830
2016 Q1	$28K	Buy	+2,161	New	+$27.6K	﹤0.01%	6394
2015 Q4	–	Sell	-2,054	Closed	-$61K	–	9547
2015 Q3	$61K	Buy	+2,054	New	+$70K	﹤0.01%	7433
2013 Q3	–	Sell	-1,214	Closed	-$49K	–	6996
2013 Q2	$49K	Buy	+1,214	New	+$53.9K	﹤0.01%	5687

Other funds holding ROSG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HCM

Highlander Capital Management Short Hills, New Jersey $292M AUM 22.24% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Citadel Advisors's ROSG Position: Q1 2017 in Review

Citadel Advisors sold out of Rosetta Genomics Ltd. (ROSG) in Q1 2017, closing a stake of 3,545 shares — an estimated $18K sold.

Citadel Advisors first reported a position in ROSG in Q2 2013 and held it in 4 quarters. The position peaked at $61K in Q3 2015. 9 funds tracked by Wall St. Rank hold ROSG as of Q1 2017.

Citadel Advisors reported no remaining Rosetta Genomics Ltd. position as of Q1 2017 after selling out during the quarter.
Citadel Advisors sold 3,545 Rosetta Genomics Ltd. shares in Q1 2017, an estimated $18K.
Citadel Advisors first reported a position in Rosetta Genomics Ltd. in Q2 2013 and held it in 4 quarters.
Citadel Advisors's Rosetta Genomics Ltd. position peaked at $61K in Q3 2015.
9 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q1 2017.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.